Bisphosphonate associated osteonecrosis of the jaw

Aliya A. Khan, George K B Sándor, Edward Dore, Archibald D. Morrison, Mazen Alsahli, Faizan Amin, Edmund Peters, David A. Hanley, Sultan R. Chaudry, Brian Lentle, David W. Dempster, Francis H. Glorieux, Alan J. Neville, Reena M. Talwar, Cameron M. Clokie, Majd Al Mardini, Terri Paul, Sundeep Khosla, Robert G. Josse, Susan Sutherland & 10 others David K. Lam, Robert P. Carmichael, Nick Blanas, David Kendler, Steven Petak, Louis Georges Ste-Marie, Jacques Brown, A. Wayne Evans, Lorena Rios, Juliet E. Compston

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

In 2003, the first reports describing osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonates (BP) were published. These cases occurred in patients with cancer receiving high-dose intravenous BP; however, 5% of the cases were in patients with osteoporosis receiving low-dose bisphosphonate therapy. We present the results of a systematic review of the incidence, risk factors, diagnosis, prevention, and treatment of BP associated ONJ. We conducted a comprehensive literature search for relevant studies on BP associated ONJ in oncology and osteoporosis patients published before February 2008.All selected relevant articles were sorted by area of focus. Data for each area were abstracted by 2 independent reviewers. The results showed that the diagnosis is made clinically. Prospective data evaluating the incidence and etiologic factors are very limited. In oncology patients receiving high-dose intravenous BP, ONJ appears to be dependent on the dose and duration of therapy, with an estimated incidence of 1%-12% at 36 months of exposure. In osteoporosis patients, it is rare, with an estimated incidence < 1 case per 100,000 person-years of exposure. The incidence of ONJ in the general population is not known. Currently, there is insufficient evidence to confirm a causal link between low-dose BP use in the osteoporosis patient population and ONJ. We concluded BP associated ONJ is associated with high-dose BP therapy primarily in the oncology patient population. Prevention and treatment strategies are currently based on expert opinion and focus on maintaining good oral hygiene and conservative surgical intervention. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)478-490
Number of pages13
JournalJournal of Rheumatology
Volume36
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Bisphosphonate-Associated Osteonecrosis of the Jaw
Diphosphonates
Jaw
Osteoporosis
Osteonecrosis
Incidence
Population
Therapeutics
Oral Hygiene
Expert Testimony
Rheumatology

Keywords

  • Bisphosphonates
  • Epidemiology
  • Guidelines
  • Osteonecrosis of the jaw
  • Side effects

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Khan, A. A., Sándor, G. K. B., Dore, E., Morrison, A. D., Alsahli, M., Amin, F., ... Compston, J. E. (2009). Bisphosphonate associated osteonecrosis of the jaw. Journal of Rheumatology, 36(3), 478-490. https://doi.org/10.3899/jrheum.080759

Bisphosphonate associated osteonecrosis of the jaw. / Khan, Aliya A.; Sándor, George K B; Dore, Edward; Morrison, Archibald D.; Alsahli, Mazen; Amin, Faizan; Peters, Edmund; Hanley, David A.; Chaudry, Sultan R.; Lentle, Brian; Dempster, David W.; Glorieux, Francis H.; Neville, Alan J.; Talwar, Reena M.; Clokie, Cameron M.; Al Mardini, Majd; Paul, Terri; Khosla, Sundeep; Josse, Robert G.; Sutherland, Susan; Lam, David K.; Carmichael, Robert P.; Blanas, Nick; Kendler, David; Petak, Steven; Ste-Marie, Louis Georges; Brown, Jacques; Evans, A. Wayne; Rios, Lorena; Compston, Juliet E.

In: Journal of Rheumatology, Vol. 36, No. 3, 03.2009, p. 478-490.

Research output: Contribution to journalArticle

Khan, AA, Sándor, GKB, Dore, E, Morrison, AD, Alsahli, M, Amin, F, Peters, E, Hanley, DA, Chaudry, SR, Lentle, B, Dempster, DW, Glorieux, FH, Neville, AJ, Talwar, RM, Clokie, CM, Al Mardini, M, Paul, T, Khosla, S, Josse, RG, Sutherland, S, Lam, DK, Carmichael, RP, Blanas, N, Kendler, D, Petak, S, Ste-Marie, LG, Brown, J, Evans, AW, Rios, L & Compston, JE 2009, 'Bisphosphonate associated osteonecrosis of the jaw', Journal of Rheumatology, vol. 36, no. 3, pp. 478-490. https://doi.org/10.3899/jrheum.080759
Khan AA, Sándor GKB, Dore E, Morrison AD, Alsahli M, Amin F et al. Bisphosphonate associated osteonecrosis of the jaw. Journal of Rheumatology. 2009 Mar;36(3):478-490. https://doi.org/10.3899/jrheum.080759
Khan, Aliya A. ; Sándor, George K B ; Dore, Edward ; Morrison, Archibald D. ; Alsahli, Mazen ; Amin, Faizan ; Peters, Edmund ; Hanley, David A. ; Chaudry, Sultan R. ; Lentle, Brian ; Dempster, David W. ; Glorieux, Francis H. ; Neville, Alan J. ; Talwar, Reena M. ; Clokie, Cameron M. ; Al Mardini, Majd ; Paul, Terri ; Khosla, Sundeep ; Josse, Robert G. ; Sutherland, Susan ; Lam, David K. ; Carmichael, Robert P. ; Blanas, Nick ; Kendler, David ; Petak, Steven ; Ste-Marie, Louis Georges ; Brown, Jacques ; Evans, A. Wayne ; Rios, Lorena ; Compston, Juliet E. / Bisphosphonate associated osteonecrosis of the jaw. In: Journal of Rheumatology. 2009 ; Vol. 36, No. 3. pp. 478-490.
@article{deef0aa55ba545f4a5e6f444ff091111,
title = "Bisphosphonate associated osteonecrosis of the jaw",
abstract = "In 2003, the first reports describing osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonates (BP) were published. These cases occurred in patients with cancer receiving high-dose intravenous BP; however, 5{\%} of the cases were in patients with osteoporosis receiving low-dose bisphosphonate therapy. We present the results of a systematic review of the incidence, risk factors, diagnosis, prevention, and treatment of BP associated ONJ. We conducted a comprehensive literature search for relevant studies on BP associated ONJ in oncology and osteoporosis patients published before February 2008.All selected relevant articles were sorted by area of focus. Data for each area were abstracted by 2 independent reviewers. The results showed that the diagnosis is made clinically. Prospective data evaluating the incidence and etiologic factors are very limited. In oncology patients receiving high-dose intravenous BP, ONJ appears to be dependent on the dose and duration of therapy, with an estimated incidence of 1{\%}-12{\%} at 36 months of exposure. In osteoporosis patients, it is rare, with an estimated incidence < 1 case per 100,000 person-years of exposure. The incidence of ONJ in the general population is not known. Currently, there is insufficient evidence to confirm a causal link between low-dose BP use in the osteoporosis patient population and ONJ. We concluded BP associated ONJ is associated with high-dose BP therapy primarily in the oncology patient population. Prevention and treatment strategies are currently based on expert opinion and focus on maintaining good oral hygiene and conservative surgical intervention. The Journal of Rheumatology",
keywords = "Bisphosphonates, Epidemiology, Guidelines, Osteonecrosis of the jaw, Side effects",
author = "Khan, {Aliya A.} and S{\'a}ndor, {George K B} and Edward Dore and Morrison, {Archibald D.} and Mazen Alsahli and Faizan Amin and Edmund Peters and Hanley, {David A.} and Chaudry, {Sultan R.} and Brian Lentle and Dempster, {David W.} and Glorieux, {Francis H.} and Neville, {Alan J.} and Talwar, {Reena M.} and Clokie, {Cameron M.} and {Al Mardini}, Majd and Terri Paul and Sundeep Khosla and Josse, {Robert G.} and Susan Sutherland and Lam, {David K.} and Carmichael, {Robert P.} and Nick Blanas and David Kendler and Steven Petak and Ste-Marie, {Louis Georges} and Jacques Brown and Evans, {A. Wayne} and Lorena Rios and Compston, {Juliet E.}",
year = "2009",
month = "3",
doi = "10.3899/jrheum.080759",
language = "English (US)",
volume = "36",
pages = "478--490",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "3",

}

TY - JOUR

T1 - Bisphosphonate associated osteonecrosis of the jaw

AU - Khan, Aliya A.

AU - Sándor, George K B

AU - Dore, Edward

AU - Morrison, Archibald D.

AU - Alsahli, Mazen

AU - Amin, Faizan

AU - Peters, Edmund

AU - Hanley, David A.

AU - Chaudry, Sultan R.

AU - Lentle, Brian

AU - Dempster, David W.

AU - Glorieux, Francis H.

AU - Neville, Alan J.

AU - Talwar, Reena M.

AU - Clokie, Cameron M.

AU - Al Mardini, Majd

AU - Paul, Terri

AU - Khosla, Sundeep

AU - Josse, Robert G.

AU - Sutherland, Susan

AU - Lam, David K.

AU - Carmichael, Robert P.

AU - Blanas, Nick

AU - Kendler, David

AU - Petak, Steven

AU - Ste-Marie, Louis Georges

AU - Brown, Jacques

AU - Evans, A. Wayne

AU - Rios, Lorena

AU - Compston, Juliet E.

PY - 2009/3

Y1 - 2009/3

N2 - In 2003, the first reports describing osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonates (BP) were published. These cases occurred in patients with cancer receiving high-dose intravenous BP; however, 5% of the cases were in patients with osteoporosis receiving low-dose bisphosphonate therapy. We present the results of a systematic review of the incidence, risk factors, diagnosis, prevention, and treatment of BP associated ONJ. We conducted a comprehensive literature search for relevant studies on BP associated ONJ in oncology and osteoporosis patients published before February 2008.All selected relevant articles were sorted by area of focus. Data for each area were abstracted by 2 independent reviewers. The results showed that the diagnosis is made clinically. Prospective data evaluating the incidence and etiologic factors are very limited. In oncology patients receiving high-dose intravenous BP, ONJ appears to be dependent on the dose and duration of therapy, with an estimated incidence of 1%-12% at 36 months of exposure. In osteoporosis patients, it is rare, with an estimated incidence < 1 case per 100,000 person-years of exposure. The incidence of ONJ in the general population is not known. Currently, there is insufficient evidence to confirm a causal link between low-dose BP use in the osteoporosis patient population and ONJ. We concluded BP associated ONJ is associated with high-dose BP therapy primarily in the oncology patient population. Prevention and treatment strategies are currently based on expert opinion and focus on maintaining good oral hygiene and conservative surgical intervention. The Journal of Rheumatology

AB - In 2003, the first reports describing osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonates (BP) were published. These cases occurred in patients with cancer receiving high-dose intravenous BP; however, 5% of the cases were in patients with osteoporosis receiving low-dose bisphosphonate therapy. We present the results of a systematic review of the incidence, risk factors, diagnosis, prevention, and treatment of BP associated ONJ. We conducted a comprehensive literature search for relevant studies on BP associated ONJ in oncology and osteoporosis patients published before February 2008.All selected relevant articles were sorted by area of focus. Data for each area were abstracted by 2 independent reviewers. The results showed that the diagnosis is made clinically. Prospective data evaluating the incidence and etiologic factors are very limited. In oncology patients receiving high-dose intravenous BP, ONJ appears to be dependent on the dose and duration of therapy, with an estimated incidence of 1%-12% at 36 months of exposure. In osteoporosis patients, it is rare, with an estimated incidence < 1 case per 100,000 person-years of exposure. The incidence of ONJ in the general population is not known. Currently, there is insufficient evidence to confirm a causal link between low-dose BP use in the osteoporosis patient population and ONJ. We concluded BP associated ONJ is associated with high-dose BP therapy primarily in the oncology patient population. Prevention and treatment strategies are currently based on expert opinion and focus on maintaining good oral hygiene and conservative surgical intervention. The Journal of Rheumatology

KW - Bisphosphonates

KW - Epidemiology

KW - Guidelines

KW - Osteonecrosis of the jaw

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=65649114391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649114391&partnerID=8YFLogxK

U2 - 10.3899/jrheum.080759

DO - 10.3899/jrheum.080759

M3 - Article

VL - 36

SP - 478

EP - 490

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 3

ER -